Nasdaq4d
Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...
StockStory.org on MSN19h
Regeneron’s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars
Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its ...
Regeneron's SWOT analysis: biotech giant's stock faces eylea challenges, pipeline promise
Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in recent months. According to ...
Is Regeneron Pharmaceuticals (REGN) the Best Cancer Stock to Buy According to Hedge Funds?
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and ...
Nasdaq3d
REGN Quantitative Stock Analysis - Benjamin Graham
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published ...
Nasdaq5d
Interesting REGN Put And Call Options For March 14th
Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information – REGN
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...
Morgan Stanley cuts Regeneron stock price target to $1,150
Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00. Despite the decrease, the firm maintained its Overweight rating on the NASDAQ-listed company. According to InvestingPro ...
Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Nasdaq5d
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Regeneron (REGN) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $11.69 a share five days away from its upcoming earnings release on February 4, 2025. Regeneron's ...